Large study of Novo, Lilly weight loss drugs shows decrease in risk of Alzheimer's
As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has approved Novo Nordisk’s semaglutide for heart disease and Eli Lilly’s tirzepati | An observational study from Washington University in St.
Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...
From Alzheimer's prevention to weight-loss dominance, Novo bets on innovation and share repurchases amid Medicare pressure.
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching ...
The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...
Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic top the list of 15 drugs selected for the second round of ...
A shake-up may be brewing in the market for GLP-1 diet drugs Friday, and it's making itself felt all across the field of ...
A study by the Department of Veterans Affairs says that drugs like Ozempic can do plenty more than just help with weight loss ...
Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.
Medicare announced plans to negotiate lower prices for 15 costly drugs, including Ozempic, Wegovy, and Trelegy Ellipta, ...
We recently published a list of These 10 Firms Took A Hit on Friday. In this article, we are going to take a look at where ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback